Clinical Trial

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the long-term safety and tolerability of Staccato alprazolam.
Protocol Amendment History 2 changes
notable Trial sites reduced: 140 -> 137 locations 2026-08-15
notable Trial sites reduced: 146 -> 140 locations 2026-08-01
Trial Details
NCT Number NCT05076617
Lead Sponsor UCB Biopharma SRL
Conditions Stereotypical Prolonged Seizures
Enrollment 300 participants
Start Date 2022-02-03
Primary Completion 2028-11-30 (estimated)
Study Completion 2028-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-14